Navigation Links
Fixed C-Arms Revolutionize Operating Room Environments

US market for fixed C-arms to grow over 5% annually over the next five

years, according to Millennium Research Group

WALTHAM, Mass., Feb. 21 /PRNewswire/ -- According to Millennium Research Group's Global Markets for C-Arms 2008 report, the US market for fixed C-arm systems, comprising units used for cardiology, angiography, and neuroradiology procedures, was valued at over $1.4 billion in 2007 and will rise to over $1.8 billion by 2012.

In the US, several hospitals have begun using fixed C-arms in operating room (OR) environments. This trend has emerged as a result of the physician movement towards collaborative surgeries, in which many specialists work together to perform complex procedures. The installation of a C-arm system in the OR allows for the ideal imaging environment for this approach.

"A fixed C-arm offers the advanced imaging capabilities required to treat many complex procedures," says Ryan Goren, Analyst at Millennium Research Group. "These systems provide surgeons with the best imaging experience possible when performing complex interventional procedures, such as interventional cardiology and interventional radiology."

The Global Markets for C-Arms report includes coverage of US, Europe (France, Germany, Italy, and the UK), and Asia Pacific (Japan, China, India, Singapore, South Korea, and Taiwan). The report provides coverage of all key industry competitors, including GE Healthcare, Philips Healthcare, Siemens Healthcare, Toshiba Healthcare, and Shimadzu.

About C-Arms

Fixed C-arms are X-ray systems used in complex angiography, cardiology, and neuroradiology procedures. Single-plane systems consist of a single C-arm, while biplane systems comprise two C-arms mounted at a 90-degree angle in relation to each other. Fixed C-arm systems are used to guide surgeons performing interventional procedures. Modern flat-panel detector systems provide surgeons with superior image quality when performing complex, time-sensitive procedures.

About Millennium Research Group

Millennium Research Group (, a Decision Resources, Inc. company (, is the global authority on medical technology market intelligence and a leading provider of strategic information to the health care sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the company provides its clients with the benefits of its specialized industry expertise through published reports and customized consulting services.

All company, brand, or product names contained in this document may be

trademarks or registered trademarks of their respective holders

For more information, contact:

Amy Krohn

Millennium Research Group

416-364-7776 x101

SOURCE Millennium Research Group
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
2. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
3. 3-D photonic crystals will revolutionize telecommunications
4. Siemens New S Class Revolutionizes the Paradigm of Ultrasound Workflow Today and Tomorrow
5. Nanotechnology innovation may revolutionize gene detection in a single cell
6. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
7. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
8. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
9. Novo Nordisk Increased Operating Profit by 11% in the First Nine Months of 2007 Based on a 9% Sales Increase and an Improved Gross Margin
10. Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
11. Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer
Post Your Comments:
(Date:11/25/2015)... November 26, 2015 ... Market 2016 - 2020 report analyzes that automating ... and quality in long-term samples, minimizing manual errors, ... Automation minimizes manual errors such as mislabeling or ... Further, it plays a vital role in blood ...
(Date:11/25/2015)... 2 nouvelles études permettent d ... différences entre les souches bactériennes retrouvées dans la plaque ... humains . Ces recherches  ouvrent une nouvelle ... charge efficace de l,un des problèmes de santé ... .    --> 2 nouvelles études permettent d ...
(Date:11/25/2015)... ANGELES and HOLLISTON, Mass. ... Technology, Inc. (Nasdaq: HART ), a biotechnology company ... that CEO Jim McGorry will present at ... December 1, 2015 at 2:30 p.m. PT. The presentation ... below) for 30 days. Management will also be available ...
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
Breaking Biology Technology:
(Date:11/16/2015)... 16, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced expansion of its TDDI product portfolio ... controller and display driver integration (TDDI) solutions designed ... new TDDI products add to the previously-announced ... (WQHD resolution), and TD4322 (FHD resolution) solutions. All ...
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
Breaking Biology News(10 mins):